Showing 2620 results
- https://www.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine-prevention-ema-filing-acceptanceAMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance Filing is supported by a comprehensive clinical…
- https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients-majority-12-week-injection-intervalRTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4] 57% and…
- https://www.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not-receiving-any-treatment-despite-significant-disease-burdenUrgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
- https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathon-biosimilar-rituximab-treat-blood-cancers-and-immunological-diseasesEuropean Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
- https://www.novartis.com/news/media-releases/novartis-international-ag-new-patient-survey-highlights-need-more-action-help-severe-asthma-patients-gain-control-their-diseaseLarge-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-perceived…
- https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskusFDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference…
- https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-sustained-improvements-signs-and-symptoms-both-and-psa-80-patients-3-yearsCosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data show…
- https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine-prevention-american-headache-society-annual-meetingData from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)…
- https://www.novartis.com/news/media-releases/novartis-interim-results-from-global-pivotal-ctl019-trial-show-durable-complete-responses-adults-rr-dlbclAt interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43%…
- https://www.novartis.com/news/media-releases/novartis-drug-tasigna-receives-eu-approval-inclusion-treatment-free-remission-tfr-data-product-labelTasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials…